RxDoctor Payments Data

Jessica Finnerty, DO

Family Medicine · Shelby Township, MINPI 1730530270

Payments from drug & device makers

$2,713in general payments, 2019–2025

Across 119 payments — averaging $22.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$531
  • Novo Nordisk$342
  • Abbott$261
  • Amgen$233
  • Lilly USA, LLC$180
  • Biohaven Pharmaceuticals, Inc.$145
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$2,713100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,713 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$41,507
Medicare patients
188
Services billed
1,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$52,060
MounjaroTirzepatide36$40,653
OzempicSemaglutide18$29,056
XareltoRivaroxaban18$23,689
JardianceEmpagliflozin17$22,713
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$19,885
JanuviaSitagliptin Phosphate14$18,625
Levothyroxine Sodium182$2,211
Albuterol Sulfate HfaAlbuterol Sulfate41$1,998
Atorvastatin Calcium155$1,948
Metoprolol Succinate96$1,882
Losartan Potassium108$1,613
Trazodone Hcl21$1,610
Omeprazole82$1,484
Pantoprazole Sodium51$1,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$86$52,06041 claims
Lilly USA, LLCMounjaro$180$40,65336 claims
Novo NordiskOzempic$342$29,05618 claims
Boehringer IngelheimJardiance$49$22,71317 claims
GSKTrelegy Ellipta$122$19,88515 claims
AbbVieSynthroid$531$1,11215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Shelby Township

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →